Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates
Item
Click for External Resource*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
HyperlinkTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Title
Independent monitoring board recommends early termination of Ebola therapeutics trial in DRC because of favorable results with two of four candidates
Subject
Description
The Pamoja Tulinde Maisha (PALM [together save lives]) study is a randomized, controlled trial of four investigational agents (ZMapp, remdesivir, mAb114 and REGN-EB3) for the treatment of patients with Ebola virus disease. The study began on Nov. 20, 2018 in the Democratic Republic of the Congo (DRC) as part of the emergency response to an ongoing Ebola outbreak in the North Kivu and Ituri Provinces.
Creator
Date
2019-08-12
Was this resource helpful?